Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) of the arylpropionic acid (profen) class. It is primarily used to reduce pain, swelling, and joint stiffness associated with arthritis—including rheumatoid arthritis and osteoarthritis. The drug works by inhibiting prostaglandin G/H synthase 1 and 2 (also known as cyclooxygenase-1 and -2), thereby blocking the production of prostaglandins that cause inflammation and pain. Tiaprofenic acid is administered orally, has high bioavailability (~90%), is sparingly metabolized in the liver to inactive metabolites, and most of it is excreted unchanged in urine. Long-term use can be associated with severe cystitis at a much higher rate than other NSAIDs; thus it is contraindicated in patients with cystitis or urinary tract infections[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiaprofenic acid.